News & Trends

• 302025-04

  Salubris' Novel Hypertension Drug SAL0140 Gained Clinical Trial Approval

• 172025-04

  Salubris' PCSK9 base-editing drug YOLT-101 has received NMPA acceptance for its clinical trial application

• 142025-02

  SAL0140 Clinical Trial Application Accepted by NMPA, Potential Breakthrough in Hypertension Treatment

• 202025-01

  Announcement of the Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure

• 282024-11

  Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list

• 272024-08

  Salubris obtaining the exclusive right of base editing drug YOLT-101